Aktis Oncology Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Aktis Oncology Inc (AKTS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Aktis Oncology Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 10M vs 626,421M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+40.1% annualized vs trailing 12 months), vs accelerating (+19.8%) for its tracked peer group.
- Growth: Aktis Oncology Inc generated 111.4% revenue growth year over year in Q2 2026, vs 60.2% for its tracked competitors combined.
- Profitability: Its -713.5% net margin compares with 44.0% for the peer group.
- Peer revenue share: Aktis Oncology Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.05M compares with $0.73M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AKTS Sales vs. its Competitors, Q2 2026
Aktis Oncology Inc reported revenue growth of 111.37 % year on year in Q2 2026, above its competitors' combined revenue growth of 60.22 %.
With a net margin of -713.48 %, Aktis Oncology Inc reported lower profitability than its competitors (44.00 %).
Aktis Oncology Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Aktis Oncology Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Aktis Oncology Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Aktis Oncology Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (2) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Aktis Oncology Inc's competitor groups requires a Commercial License.
For context: the Consumer Electronics industry grew revenue -0.5% year over year, combined, vs 111.4% for Aktis Oncology Inc. Aktis Oncology Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Aktis Oncology Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Aktis Oncology Inc | No | No | No | No |
| Competitors combined (43) | ||||
| High-Confidence Competitors (1) | - | - | - | |
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 12.50 % (1 of 8) | 12.50 % (1 of 8) | 62.50 % (5 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AKTS Stock Performance relative to its Competitors
AKTS Stock Performance relative to High-Confidence Competitors
AKTS Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Maxlinear Inc | 282.9% | Outperformed |
| 2 | Marvell Technology Inc | 282.9% | Outperformed |
| 3 | Silicom Ltd | 282.9% | Outperformed |
| 4 | Semtech Corp | 282.9% | Outperformed |
| 5 | Macom Technology Solutions Holdings Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Aktis Oncology Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Aktis Oncology Inc's Comment on Competition and Industry Peers
We compete directly with these companies to secure design slots inside RFFE module targeting companies that procure filters or internally source filters. While many of our competitors have more resources than we have, we believe that our filter designs will be superior in performance, and we approach prospective customers as a pure-play filter supplier, offering advantages in performance over the full frequency range at competitive costs.
Publicly Traded Peers of Aktis Oncology Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Aktis Oncology Inc | 1,073.38 | 9.66 |
| Nvidia Corp | 5,648,317.01 | 302,969.00 |
| Broadcom Inc | 1,716,167.79 | 89,104.00 |
| Texas Instruments Incorporated | 255,760.00 | 19,453.00 |
| Marvell Technology Inc | 228,222.52 | 8,715.90 |
| Amphenol Corporation | 217,810.34 | 29,010.70 |
| SUBTOTAL | 9,088,211.41 | 665,699.77 |
Sign in to see all competitors of Aktis Oncology Inc .
Sources: Aktis Oncology Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Aktis Oncology Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Aktis Oncology Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Actinium Pharmaceuticals Inc | Named by the company | 85% |
| Kyocera Corp | Named by the company | 85% |
| Ability Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Aktis Oncology Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Aktis Oncology Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Aktis Oncology Inc | 1,073 | 48,055 | -375,766 |
| Nvidia Corp | 5,648,317 | 7,213,548 | 4,592,357 |
| Broadcom Inc | 1,716,168 | 2,700,121 | 1,159,545 |
| Texas Instruments Incorporated | 255,760 | 589,485 | 183,394 |
| Marvell Technology Inc | 228,223 | 1,165,227 | 676,350 |
| Amphenol Corporation | 217,810 | 170,651 | 30,516 |
| PEERS TOTAL | 9,087,138 | 729,747 | 303,684 |
Sign in to see all peers for Aktis Oncology Inc .
Aktis Oncology Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Nvidia Corp | United States 78.13 % |
| Broadcom Inc | Asia Pacific 60.15 % |
| Marvell Technology Inc | China 43.75 % |
| Amphenol Corporation | Other foreign locations 48.31 % |
| International Business Machines Corporation | Americas 49.04 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Aktis Oncology Inc .
Aktis Oncology Inc's Business Segment Mix vs Peers
Revenue by operating segment, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Nvidia Corp | Compute and Networking 91.34 % |
| Broadcom Inc | Semiconductor Solutions 64.81 % |
| Texas Instruments Incorporated | Analog 81.33 % |
| Marvell Technology Inc | Reportable 100.00 % |
| Amphenol Corporation | Communications Solutions Segment 61.97 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Aktis Oncology Inc .
Aktis Oncology Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 54 companies in Aktis Oncology Inc's industry classification, broader than the peer set above. Market cap in millions of $.Aktis Oncology Inc ranks #0 of 54 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,781, indicating a moderately concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Qualcomm Inc | 202,771 | 30.94 % |
| 2 | Sony Group Corporation | 143,483 | 21.90 % |
| 3 | Motorola Solutions inc | 76,160 | 11.62 % |
| 4 | Nokia Corporation | 62,309 | 9.51 % |
| 5 | Ciena Corp | 1,234 | 5.2% |
| 6 | Ubiquiti Inc | 1,234 | 5.2% |
| 7 | Ericsson Lm Telephone Co | 1,234 | 5.2% |
| 8 | Fabrinet | 1,234 | 5.2% |
| 9 | Viasat Inc | 1,234 | 5.2% |
| 10 | Planet Labs Pbc | 1,234 | 5.2% |
| 0 | Aktis Oncology Inc | 940 | 0.00 % |
Market cap and industry share for the rest of Aktis Oncology Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Aktis Oncology Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Consumer Electronics industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (65 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | - | 34.70 % (avg) | - |
| Operating Margin | -939.13 % | industry median | -938.3 pp |
| EBITDA Margin | -124.85 % | -0.86 % (avg) | -124.0 pp |
| Capital Intensity (Capex / Revenue) | 67.75 % | 4.35 % (avg) | +63.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Aktis Oncology Inc's Valuation vs Competitive Position
Valuation multiples vs the Consumer Electronics industry average (65 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 45.3x | - |
| EV / EBITDA | - | 19.2x | - |
| P/B | 6.5x | 4.8x | +1.7x |
| Return on Equity | -38.75 % | industry aggregate | -68.29 % |
| Return on Invested Capital | -20.94 % | 3.80 % (avg) | -24.74 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Aktis Oncology Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2018 | 2019 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 2.40 % | 2.40 % | 70.00 % | 70.00 % | 43.12 % | 412.69 % | 113.30 % | 44.27 % |
| Operating Margin | -2,280.16 % | -2,280.16 % | -1,612.34 % | -1,612.34 % | -1,383.50 % | -479.48 % | -325.96 % | -241.98 % |
| Return on Invested Capital | -50.55 % | -50.55 % | -31.98 % | -31.98 % | -30.04 % | -21.67 % | -29.18 % | -36.19 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Aktis Oncology Inc's Strategic Group Map
Every company in Aktis Oncology Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Aktis Oncology Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Aktis Oncology Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,781 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 67.75 % vs industry average 4.35 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Aktis Oncology Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Aktis Oncology Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Aktis Oncology Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Aktis Oncology Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Aktis Oncology Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) — not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+40.1% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Operating margin 938.3 points below the industry median.
- Return on equity 68.3 points below the industry aggregate.
Opportunities
No rule matched.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Aktis Oncology Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Aktis Oncology Inc | 5.48 | 7.73 | 0.06 |
| Nvidia Corp | 0.40 | 4.07 | 0.09 |
| Broadcom Inc | 0.99 | 2.05 | 0.75 |
| Texas Instruments Incorporated | 1.09 | 4.53 | 0.88 |
| Marvell Technology Inc | 0.98 | 2.25 | 0.31 |
| Amphenol Corporation | 0.17 | 2.11 | 1.43 |
Sign in to see all peers for Aktis Oncology Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Aktis Oncology Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Aktis Oncology Inc | Q2 2026 | -62.5 % | - |
| Nvidia Corp | Q2 2026 | +105.9 % | +125.9 % |
| Broadcom Inc | Q2 2026 | +85.5 % | +216.1 % |
| Texas Instruments Incorporated | Q2 2026 | +22.8 % | +52.9 % |
| Marvell Technology Inc | Q1 2026 | +27.6 % | -70.1 % |
| Amphenol Corporation | Q2 2026 | +55.0 % | +62.1 % |
| PEERS TOTAL | +57.5 % | +113.3 % |
Sign in to see all peers for Aktis Oncology Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Aktis Oncology Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Aktis Oncology Inc | Q2 2026 | - | - |
| Nvidia Corp | Q2 2026 | +86.8 % | +41.3 % |
| Broadcom Inc | Q2 2026 | +74.0 % | +274.6 % |
| Texas Instruments Incorporated | Q2 2026 | +12.7 % | -60.6 % |
| Marvell Technology Inc | Q1 2026 | +22.8 % | +30.3 % |
| Amphenol Corporation | Q2 2026 | +44.8 % | +19.7 % |
Sign in to see all peers for Aktis Oncology Inc .
Aktis Oncology Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Aktis Oncology Inc | - | - | - |
| Nvidia Corp | 81.41% | 95.06% | 110.11% |
| Broadcom Inc | 21.57% | 24.07% | 43.74% |
| Texas Instruments Incorporated | 17.31% | 18.74% | 35.77% |
| Marvell Technology Inc | 22.14% | 25.02% | 33.73% |
| Amphenol Corporation | 13.80% | 15.13% | 37.19% |
Sign in to see all peers for Aktis Oncology Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Aktis Oncology Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Aktis Oncology Inc | - | 111.13 |
| Nvidia Corp | 29.44 | 18.64 |
| Broadcom Inc | 44.74 | 19.26 |
| Texas Instruments Incorporated | 42.31 | 13.15 |
| Marvell Technology Inc | 87.62 | 26.18 |
| Amphenol Corporation | 42.24 | 7.51 |
| PEERS AVERAGE | 32.82 | 13.65 |
Sign in to see all peers for Aktis Oncology Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.